Here, we screened patients with hematologic malignancies from the MSK-IMPACT-HEME study and uncovered what we believe to be novel FBXO11 mutations in a previously undiscovered IDR in its N-terminus. The gene discussed is FBXO11; the disease is hematologic disorder.